Armata Pharmaceuticals (ARMP) Equity Ratio (2013 - 2026)

Armata Pharmaceuticals has disclosed Equity Ratio across 14 years of filings, most recently posting 4.46 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 4.46, down 624.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 4.46 (down 624.17% YoY), and the FY2025 annual result was 2.84, down 411.8% from the prior year.
• Equity Ratio came in at 4.46 for Q1 2026 at Armata Pharmaceuticals, down from 2.84 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.57 in Q1 2022 to a low of 4.46 in Q1 2026.
• The 5-year median for Equity Ratio is 0.43 (2024), against an average of 0.58.
• Across the five-year window, Equity Ratio gained 3.42% in 2022 and sank 624.17% in 2026, its largest moves.
• Armata Pharmaceuticals' Equity Ratio stood at 0.38 in 2022, then tumbled by 186.59% to 0.33 in 2023, then sank by 70.42% to 0.56 in 2024, then plunged by 411.8% to 2.84 in 2025, then tumbled by 57.0% to 4.46 in 2026.
• The last three Equity Ratio figures came in at 4.46 (Q1 2026), 2.84 (Q4 2025), and 1.07 (Q3 2025), per Business Quant data.